Cargando…
Regression Analysis to Estimate the Factor VIII Activity of Patients with Hemophilia A Without Inhibitor who Received Emicizumab Therapy
BACKGROUND: Emicizumab, a bispecific monoclonal antibody for hemophilia A (HA), has strong pharmacodynamic effects in several coagulation assays resulting in dosing difficulties with Factor VIII (FVIII) concentrates during bleeding emergencies. MATERIALS AND METHODS: Single and multiple regression...
Autores principales: | Hatayama, Yuki, Motokura, Toru, Hosoda, Yuzuru, Suzuki, Sayaka, Namba, Hiroya, Kato, Konami, Kojima, Nao, Horie, Takuya, Iwamoto, Takuya, Yamashita, Noriko, Ichikawa, Hitomi, Fukuda, Tetsuya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894944/ https://www.ncbi.nlm.nih.gov/pubmed/35225012 http://dx.doi.org/10.1177/10760296221082992 |
Ejemplares similares
-
Absence of Effect of Emicizumab on D-Dimer Concentrations in Adult
Patients with Severe Hemophilia A
por: Iarossi, Michael, et al.
Publicado: (2022) -
Factor VIII inhibitors in hemophilia A treated with emicizumab: longitudinal follow-up of outcomes
por: Levy-Mendelovich, Sarina, et al.
Publicado: (2023) -
Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study
por: Schmitt, Christophe, et al.
Publicado: (2021) -
Verification and Comparison of Chromogenic Factor VIII Activity Assays in Patients With Hemophilia Treated With and Without Emicizumab
por: Lee, Min Young, et al.
Publicado: (2023) -
Emicizumab Associated Rhabdomyolysis in Hemophilia A
por: Wilson, Joseph A., et al.
Publicado: (2020)